MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Elenco Azioni・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Chiusa

SettoreSettore sanitario

27.74 -0.72

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.54

Massimo

27.82

Metriche Chiave
By Trading Economics
Entrata	-28M 22M
Vendite	4.3M 244M
P/E Media del settore	9.926 56.063
Margine di Profitto	9.224
Dipendenti	293
EBITDA	-22M 52M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+47.53% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	8.3M 1.6B
Apertura precedente	28.46
Chiusura precedente	27.74

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

29.8 / N/A Supporto e resistenza

Harmony Biosciences Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 apr 2026, 04:27 UTC

Principali Notizie su Eventi

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3 apr 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 18:30 UTC

Principali Notizie su Eventi

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 apr 2026, 18:14 UTC

Discorsi di Mercato

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 apr 2026, 17:50 UTC

Discorsi di Mercato

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 apr 2026, 17:44 UTC

Acquisizioni, Fusioni, Takeovers

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 apr 2026, 16:50 UTC

Principali Notizie su Eventi

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 apr 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 16:12 UTC

Utili

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 apr 2026, 15:56 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 apr 2026, 15:56 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Global Equities Roundup: Market Talk

3 apr 2026, 15:56 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2026, 15:20 UTC

Principali Notizie su Eventi

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 apr 2026, 15:08 UTC

Acquisizioni, Fusioni, Takeovers

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 apr 2026, 14:11 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 apr 2026, 12:56 UTC

Discorsi di Mercato

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 apr 2026, 08:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 08:01 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 apr 2026, 08:01 UTC

Discorsi di Mercato

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 apr 2026, 07:45 UTC

Discorsi di Mercato

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Discorsi di Mercato

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 apr 2026, 04:33 UTC

Discorsi di Mercato

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 apr 2026, 04:33 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 apr 2026, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

3 apr 2026, 04:01 UTC

Discorsi di Mercato

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3 apr 2026, 02:01 UTC

Discorsi di Mercato

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3 apr 2026, 01:59 UTC

Discorsi di Mercato

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3 apr 2026, 01:44 UTC

Discorsi di Mercato

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3 apr 2026, 01:22 UTC

Discorsi di Mercato

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Confronto tra pari

Modifica del prezzo

Harmony Biosciences Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

47.53% in crescita

Previsioni per 12 mesi

Media 41.25 USD 47.53%

Alto 62 USD

Basso 25 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

29.8 / N/ASupporto e resistenza

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.